Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc.’s Chief Financial Officer, Heather Kiessling, reported an open-market sale of 23,124 shares of common stock at a weighted average price of $6.28 per share. According to the footnotes, these were “sell to cover” trades under a Rule 10b5-1 trading plan to satisfy tax withholding from quarterly vesting of a restricted stock award.
After the transaction, she directly holds 1,526,252 shares of ASP Isotopes common stock, indicating that the sale represents a small portion of her overall equity position and is tied to a pre-arranged, tax-related mechanism rather than a discretionary reduction in holdings.
ASP Isotopes Inc. executive Donald George Ainscow, EVP, General Counsel and Secretary, reported an open-market sale of 100,000 shares of Common Stock. The weighted average sale price was $6.14 per share, with individual trades occurring between $6.11 and $6.17 per share.
Following this transaction, Ainscow directly holds 800,000 shares of ASP Isotopes Inc. common stock. The filing notes that detailed trade-by-trade pricing within the reported range is available upon request.
ASP Isotopes Inc. director Todd Wider sold 100,000 shares of Common Stock in open-market transactions. The Form 4 shows two sales of 50,000 shares each, at reported prices of $6.12 and $6.25 per share, executed as multiple trades within stated price ranges.
Footnotes explain that each reported price is a weighted average, with actual trade prices between $6.21 and $6.31 for one block and between $6.10 and $6.25 for the other. Overall, the filing reflects a net sale of 100,000 shares by the director.
ASP Isotopes Inc. director Michael Gorley sold 30,000 shares of Common Stock in an open-market transaction at a weighted average price of approximately $6.27 per share. After this sale, he directly holds 87,908 shares, indicating he retains a significant ongoing equity position.
According to the disclosure, the shares were sold in multiple trades at prices ranging from $6.10 to $6.63 per share, with the weighted average reported. The filing notes that full trade-by-trade pricing details are available upon request from the company, any stockholder, or the SEC staff.
Independent Trading Group (ITG) Inc. notice of proposed sale of Common Stock under Form 144. The filing lists proposed sale quantities of 30,000 and 186,600 shares and states 125,903,447 shares outstanding as of 06/29/2026. It also records securities acquired as compensation: 8,380 shares (08/13/2024) and 42,522 shares (11/20/2024).
The entries are shown as Restricted Stock Award acquisitions and indicate the filer is the Issuer for those awards. The filing lists securities to be sold and notes prior sales activity in the past three months.
ASP Isotopes Inc. entered into an Agreement and Plan of Merger with ENDRA Life Sciences Inc., pursuant to which ENDRA’s subsidiary Merger Sub will merge with Noble Africa LLC, with Noble surviving as a direct, wholly owned subsidiary of ENDRA. Concurrently, Noble agreed to a $50 million financing through subscription agreements for approximately 4,594,218 Class A Units (and/or pre-funded warrants) and the Company will receive 3,054,185 Class B Units in the financing and will contribute its equity interest in Renergen to Noble for 55,500,000 Class B Units. At the Effective Time ENDRA will be renamed Noble Africa Inc. and adopt an amended charter establishing Class A and Class B common stock (Class B votes 10 votes per share). Closing conditions include ENDRA stockholder approval, SEC effectiveness of a Form S-4, Nasdaq listing approval, receipt of Noble Investment proceeds, a written OPIC/DFC consent where required, and ENDRA having at least $3.8 million of cash. The Merger Agreement may be terminated if not closed by December 24, 2026.
ASP Isotopes Inc. entered into an Agreement and Plan of Merger with ENDRA Life Sciences Inc., pursuant to which ENDRA’s subsidiary Merger Sub will merge with Noble Africa LLC, with Noble surviving as a direct, wholly owned subsidiary of ENDRA. Concurrently, Noble agreed to a $50 million financing through subscription agreements for approximately 4,594,218 Class A Units (and/or pre-funded warrants) and the Company will receive 3,054,185 Class B Units in the financing and will contribute its equity interest in Renergen to Noble for 55,500,000 Class B Units. At the Effective Time ENDRA will be renamed Noble Africa Inc. and adopt an amended charter establishing Class A and Class B common stock (Class B votes 10 votes per share). Closing conditions include ENDRA stockholder approval, SEC effectiveness of a Form S-4, Nasdaq listing approval, receipt of Noble Investment proceeds, a written OPIC/DFC consent where required, and ENDRA having at least $3.8 million of cash. The Merger Agreement may be terminated if not closed by December 24, 2026.
ENDRA Life Sciences Inc. has adopted an Amended and Restated Certificate of Incorporation for Noble Africa Inc., setting a new capital structure and governance framework under Delaware law. The charter authorizes 1,250,000,000 shares split into dual‑class common stock and preferred stock.
The new structure creates Class A Common Stock with one vote per share and Class B Common Stock with ten votes per share, with automatic and voluntary conversion mechanisms into Class A. It also empowers the board to create multiple series of preferred stock, establishes a classified board, defines stockholder voting and consent rights, and includes liability protections, indemnification, corporate opportunity waivers, business combination restrictions, and Delaware‑focused forum selection clauses.
ASP Isotopes Inc. outlined a proposed merger in which its wholly owned subsidiary Noble Africa LLC would combine with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity. The combined company plans to be named Noble Africa Inc. and apply to list on Nasdaq under the ticker “NOBA.”
Alongside the merger, Noble Africa has secured commitments for a private placement expected to generate approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes as lead investor and about $30 million from other investors, with $750,000 from certain ASP Isotopes directors and management. At closing, ASP Isotopes is expected to own about 89% of the combined company, pre-closing ENDRA stockholders about 3%, and other private placement investors about 7%, with closing targeted for the third or fourth quarter of 2026, subject to regulatory and stockholder approvals and other customary conditions.